Phase 2 N=8 Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)
Mesothelioma
Primary: Tumor Response Rate Following Zoledronic Acid (Zometa) — 12.5 percentage of responders
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=32 Azacitidine and Etanercept in Treating Patients With Myelodysplastic Syndromes
de Novo Myelodysplastic Syndromes · Previously Treated Myelodysplastic Syndromes · Secondary Myelodysplastic Syndromes
Primary: Frequency of Hematologic Responses, as Defined by International Working Group (IWG) Criteria — 14; 8; 1; 7 Participants
Phase 2 N=43 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
Adult Nasal Type Extranodal NK/T-cell Lymphoma · Anaplastic Large Cell Lymphoma · Angioimmunoblastic T-cell Lymphoma
Primary: Successful Mobilization and Collection of PBSCs — 34 Participants
N/A N=65 Computer-Assisted Navigation for Intramedullary Nail Fixation of Intertrochanteric Femur Fractures
Intertrochanteric Femur Fractures
Primary: Tip-to-apex Distance — 14.1; 14.9 mm
Phase 2 N=195 Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC)
Metastatic Non-squamous Non Small Cell Lung Cancer
Primary: The Primary Efficacy Endpoint is Progression Free Survival, Analyzed in the Treated Population. PFS is Assessed From Randomization Until Either Tumor Progression, as Per…
Phase 4 N=42 Validation of a Real-time Urodynamic Measure of Urinary Urgency
Overactive Bladder Syndrome
Primary: Change in Maximal Cystometric Capacity (mL) — 95; 473.50 milliliters (mL) — p=.005
Phase 3 N=41 Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis
Cystinosis
Primary: Average Difference Between Morning and Non-Morning Log White Blood Cell (WBC) Cystine Values — -0.229; 0.080 log [nmol ½ cystine/mg protein] — p=0.0048
Phase 2 N=23 Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
Hormone-Resistant Prostate Cancer · Recurrent Prostate Carcinoma
Primary: PSA Response Rate — 1; 2 Participants
Phase 2 N=39 Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 8.5 months
N/A N=200 Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation
Persistent Atrial Fibrillation
Primary: Number of Participants With 1 Year Freedom From AF / AT — 65; 62; 27; 31 participants
N/A N=110 Investigation of Intravenous Tranexamic Acid With Anatomic and Reverse Total Shoulder Arthroplasty
Blood Loss · Anatomic Total Shoulder Arthroplasty · Reverse Total Shoulder Arthroplasty
Primary: Post-operative Blood Loss — 152.2; 178.0 mL
Phase 3 N=651 Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age
Herpes Zoster · Herpes Zoster Vaccine
Primary: Number of Subjects With Anti-gE Antibody Concentrations Equal to or Above the Cut-off Value — 210; 210; 202 Subjects
Phase 2 N=29 Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria
Progeria · Hutchinson-Gilford Syndrome
Primary: Proportion of Participants With Successful Rate of Weight Gain — 0.36 proportion of participants
N/A N=1,298 Evaluating a Telephone-Based Smoking Cessation Program Among People in the Military (The AFIII Study)
Smoking · Smoking Cessation
Primary: Continuous Abstinence — 173; 136 Participants
N/A N=60 Evaluation of the PelvicSim Simulator for Training in Intrauterine Device Insertions
Contraceptive Devices, Intrauterine · Education, Medical
Primary: Insertion Score Before and Immediately After Initial Practice (Same Day), and 3 Months After Initial Practice — 61.5; 67.5; 82.5; 83 Percent of tasks performed correctly